@Article{096504018X15235274183790,
AUTHOR = {Pedro Fong,
 Cheng N. Ao,
 Kai I. Tou, Ka M. Huang, Chi C. Cheong, Li R. Meng},
TITLE = {Experimental and In Silico Analysis of Cordycepin and its Derivatives  as Endometrial Cancer Treatment},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {2},
PAGES = {237--251},
URL = {http://www.techscience.com/or/v27n2/48649},
ISSN = {1555-3906},
ABSTRACT = {The aim of this study was to investigate the inhibition effects of cordycepin and its derivatives on endometrial 
cancer cell growth. Cytotoxicity MTT assays, clonogenic assays, and flow cytometry were used to observe 
the effects on apoptosis and regulation of the cell cycle of Ishikawa cells under various concentrations of 
cordycepin, cisplatin, and combinations of the two. Validated in silico docking simulations were performed 
on 31 cordycepin derivatives against adenosine deaminase (ADA) to predict their binding affinities and hence 
their potential tendency to be metabolized by ADA. Cordycepin has a significant dose-dependent inhibitory 
effect on cell proliferation. The combination of cordycepin and cisplatin produced greater inhibition effects 
than did cordycepin alone. Apoptosis investigations confirmed the ability of cordycepin to induce the apoptosis of Ishikawa cells. The in silico results indicate that compound MRS5698 is least metabolized by ADA 
and has acceptable drug likeness and safety profiles. This is the first study to confirm the cytotoxic effects of 
cordycepin on endometrial cancer cells. This study also identified cordycepin derivatives with promising pharmacological and pharmacokinetic properties for further investigation in the development of new treatments for 
endometrial cancer},
DOI = {10.3727/096504018X15235274183790}
}